SiNtx Technologies Inc (SINT)

[boston745]

Why was Sintx ties to Zimmer purposefully removed from Sintx's IPO paperwork in 2013? Look at the summary Dr Link background for the 2007 IPO and compare that to the disclosure in the 2013 IPO paperwork. You will see that in the 2013 paperwork it was purposefully withheld that Zimmer acquired Centerpulse when Dr. Link was CEO of Centerpulse. Even how Centerpulse is described is vastly different between 2007/2013 paperwork. Theres a reason for this change. Add to that that current Chairman/former CEO Dr Bal's background with Zimmer was not disclosed despite this information being disclosed about Dr Hofmann.
Any investigation is unfortunately going to need to start right here as i suspect this is a breach of disclosure required. Most likely a small infraction. There is enough evidence to suggest intent.
If there was some sort of deal made years ago this could be part of it as hiding this connection has been key in short and distorting SINT/AMDA.

Dr. Max Link, PHD (Chairman 2003-2014)

Max Link, Ph.D. has served as the Chairman of our board of directors since October 2003. Dr. Link served as Chairman of the Board and Chief Executive Officer of Centerpulse AG, the largest orthopedics company in Europe, from March 2002 until October 2003, when Centerpulse was acquired by Zimmer Holdings, Inc. Prior to joining Centerpulse,

Max E. Link, Ph.D. has served as the chairman of our board of directors since October 2003. Dr. Link was chairman of the board of directors and Chief Executive Officer of Centerpulse AG, a medical implant company from March 2002 to October 2003. Prior to joining Centerpulse,

Next if you look at the summary of Dr Aaron Hofmann, cofounder of Sintx and a member of the board of Sintx when Sintx first tried to IPO, you'll see inclusion of him being a surgeon designer for Zimmer in the 2007 IPO paperwork. Yet the information about Dr Sonny Bal, also a board member, the fact that hes a surgeon designer for Zimmer in the 2013 IPO paperwork is not disclosed.

Dr. Hofmann, MD

Aaron A. Hofmann, M.D. is our co-founder and has been a member of our board of directors since 1996. Dr. Hofmann is a nationally and internationally recognized orthopedic surgeon, known for his accomplishments in developing total hip and knee replacement systems, innovative surgical approaches in hip and knee surgery and basic research on human bone dynamics. Dr. Hofmann holds 14 patents, many of which are directed at inventions involving hip and knee implants. Since 2003, Dr. Hofmann has been a design surgeon for Zimmer Holdings, Inc., the largest orthopedics company in the world. Dr. Hofmann, working with a team of orthopedic surgeons, helped design Zimmer’s new gender knee specifically designed for women.

B. Sonny Bal, M.D. has served on our board of directors since February 2012. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, and a J.D. from the University of Missouri. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.

We believe that Dr. Bal’s expertise in orthopedic surgery and his specialty in hip and knee replacement surgery qualifies him to serve on our board of directors.

Per Dr Bals resume:

Designer Surgeon Panel, Zimmer Inc., Warsaw, Indiana, 2002 to present.

Total Joint Reconstruction Clinical Advisory Panel, Amedica Inc., Salt Lake City, UT, 2005 to present.

1. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73
2. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89
3. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 74
4. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 90
5. https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf

========================================

A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

Silicon Nitride = Next Gen Hip implant material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353

Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294

Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136

Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:

Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529

Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867

Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439

Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.

One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant